Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2013  |  Volume : 9  |  Issue : 4  |  Page : 653-659

Zoledronic acid treatment for cancerous bone metastases: a phase IV study in Taiwan


1 Department of Urology, Chang Gung Medical Foundation-Kaohsiung Branch, Taiwan
2 General Surgery, China Medical University Hospital, Taiwan
3 Radiology-Oncology, Mackey Memorial Hospital, Taiwan
4 Chang Gung Medical Foundation-LinKou Branch, Taiwan
5 Taipei Veterans General Hospital, Taiwan
6 Hematology-Oncology, Kuang Tien General Hospital, Taiwan
7 Tai-An Hospital, Taiwan
8 Chang Gung Medical Foundation-Keelung Branch, Taiwan
9 Tri-Service General Hospital, Taiwan
10 Medicine, Shuang Ho Hospital, Taipei Medical University, Taiwan

Correspondence Address:
Tsu-Yi Chao
Division of Hematology/Oncology, Department of Medicine, Shuang Ho Hospital, Taipei Medical University, No. 291, Chung Cheng Road, Chung Ho 235, New Taipei City
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.126471

Rights and Permissions

Aim of study: To investigate the features, adverse effects, bone marker changes in patients with breast cancer, prostate cancer, and multiple myeloma with bone metastases under Zometa® therapy. Materials and Methods: This post-marketing study included 414 Taiwanese patients with bone metastases secondary to breast cancer, prostate cancer, or multiple myeloma who received Zometa® for 48 weeks. The patients' characteristics, medication and adverse events were recorded, meanwhile changes in four serum bone metabolic markers and pain reduction were assessed every three months for one year. Results: A total of 3,711 doses of Zometa® were infused, accounting for 294.5 patient-years. Adverse events occurred in 9.4% of patients, with bone pain, insomnia, constipation, and pyrexia as the most frequently reported. There was no osteonecrosis of the jaw. The incidence of skeletal-related events decreased significantly from 44.9% to 18.8%. Serum NTx, BAP, and TRACP5b steadily decreased to nadir at six months, but serum OPG was persistently elevated until the end of one year. The average decrease in pain score was 14.1, 14.3, and 16.7 for prostate cancer, breast cancer, and multiple myeloma patients, respectively. Conclusion: Zometa® can be safely administered in Taiwanese patients with bone metastases secondary to breast cancer, prostate cancer, and multiple myeloma. There are concomitant decreases in skeletal-related events and bone pain.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2993    
    Printed107    
    Emailed1    
    PDF Downloaded214    
    Comments [Add]    
    Cited by others 2    

Recommend this journal